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Abstract
Background In recent years, differential analysis of proteins
from human saliva, i.e., proteomic analysis, has received
much attention mainly due to its unstressful sampling and
its great potential for biomarker research. It is widely
considered that saliva is a highly stable medium for proteins
thanks to a large amount of antiprotease agents, even at
ambient and physiological temperatures.
Objective To find the best protocol for the handling of
samples, we have investigated the stability of saliva proteins
stored at different temperatures (from −80 to 20°C) by one-
and two-dimensional electrophoresis.
Results At 20°C, no major changes were observed on
protein one-dimensional profiles following 1 day of storage;
however, between 7 days and 30 days, the native alpha-
amylase band decreased slightly to give several bands with
molecular weight between 35 and 25 kDa. The same
phenomenon appeared after 30 days of storage at 4°C.
Two-dimensional analysis of salivary maps revealed degra-
dation from day 7 of several protein groups for samples
stored at 20°C.
Conclusion All these findings have to be carefully consid-
ered when saliva is collected for clinical proteomic
analysis. We can conclude that, to maintain the optimum
stability of saliva proteins, saliva samples should be
collected on ice followed by the addition of protease in-
hibitor cocktail, centrifuged to remove insoluble material,
and stored at −20 or −80°C.











Saliva has become popular in recent decades as a medium
for the measurement of numerous biomolecules [1–4]. The
greatest advantage, when compared to blood sample
collection, is that saliva is readily accessible and collectible.
Consequently, it can be used in clinically difficult situa-
tions, such as in children, handicapped, and anxious
patients, where blood sampling could be a difficult act to
perform [5].
A wide range of biomolecules are now monitored in
saliva [6, 7]. Proteins and peptides were extensively studied
in saliva for biomarker research; these include the quanti-
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fication of steroid hormones such as cortisol or progester-
one [8–11], and the detection of various therapeutic or illicit
drugs [12]. Tumor markers that were identified in saliva
have been used to screen malignant diseases [13–15].
Antibodies against viruses and viral components can also
be detected in saliva, therefore making it easier to diagnose
various infections such as, for example, hepatitis A, B, or
C; HIV; rubella; and dengue [16–19]. Identification of all
saliva proteins [20–39] allowed comparative analysis of
proteomic maps of healthy and ill people, which revealed
differentially expressed proteins as potential biomarkers
[26, 28, 32, 35, 36, 38].
On a recent summary about the proteomic technologies
currently used, Hu et al. pointed out the critical challenges
and perspectives for this emerging field [40]. The first point
was the need to standardize the sample collection, prepa-
ration, and handling procedures. Indeed, to ensure compa-
rable analyses of saliva and, thus, results between studies
and labs, careful attention to methodological detail is
required. Collection, storage conditions, and processing of
saliva samples are key steps to guarantee reproducibility
and validity of measurements [40–42].
In addition to salivary gland secretions (water, proteins,
enzymes, electrolytes, and small organic molecules), blood
derivatives from gingival crevicular fluid or oral wounds,
bacteria, fungi, desquamated epithelial cells, expectorated
bronchial and nasal secretions, or food debris have also
been found in saliva [4]. Many of these components may
have damaged molecules of interests for proteomic analy-
sis. Careful control of temperature during saliva collection
and salivary sample storage is crucial; additionally, most
insoluble materials can be eliminated by centrifugation or
filtration. The use of a protease inhibitor cocktail can help
to reduce protein degradation during saliva sample collec-
tion and processing. A review of previous protocols used
for proteomic analysis of saliva showed variations in
several parameters such as temperature at sample collec-
tion, the addition of a protease inhibitor cocktail, the
removal of insoluble material and the temperature of
storage of saliva samples (Table 1). This can be explained
by the fact that, for many decades, it was largely believed
that saliva contains a high amount of protease inhibitors,
which confers a great stability on proteins.
Saliva storage protocols have been extensively analyzed
for the stability of steroids [43], progesterone [44, 45],
immunoglobulin A and lysozyme [46], RNA of hepatitis C
virus, and blood group antigen detection [47, 48], but never
for a proteome analysis, with the exception of Schipper
et al. [39], who recently showed differences on surface
enhanced laser desorption/ionization-time-of-flight (TOF)
mass spectra of saliva samples as a function of storage
temperature, centrifugation speed, and the use of protease
inhibitors.
In the present paper, we propose to study the stability of
the major salivary proteins stored at various storage
temperatures (−80, −20, 4, and 20°C) by one-dimensional
and bidimensional electrophoresis to estimate the rate of
stability of saliva proteins and, in the case of degradation,
which proteins or group of proteins were the most
susceptible. The aim of this work is to establish a robust
and standardized protocol for collection and storage of




Whole saliva was collected from a healthy subject 2 h after
breakfast time. Before sample collection, the subjects
brushed their teeth and rinsed their mouth with water. To
help saliva production, individuals drank a glass of water
15 min before collection, and then, stimulated saliva was
collected on ice for 5 min by chewing on paraffin wax and
spitting intermittently. Saliva samples were centrifuged at
15,000×g for 15 min at 4°C to eliminate insoluble material.
A sample was kept with insoluble material (without the
centrifugation step) to investigate the influence of bacteria,
mucine, and other insoluble material on protein stability.
Storage Kinetics of Saliva
Clear saliva was aliquoted (1 ml) into microcentrifuge tubes
and stored at either 4°C or ambient temperature. At regular
intervals (10 min, 1 h, 1 day, 7 days, 30 days), samples
were placed in a −20°C freezer until further analysis by
mono- and two-dimensional electrophoresis. A sample with
protease inhibitor mixture (Complete®, Roche, Penzberg,
Germany) was also prepared and placed at ambient
temperature for 30 days. Control samples were also stored
at either −80 or −20°C for 30 days.
Extraction of Salivary Protein
Proteins were first extracted using the trichloroacetic acid
(TCA)/acetone method [49]. Briefly, proteins were preci-
pitated using 90% acetone (v/v), 10% TCA (v/v), and
0.07% 2-mercaptoethanol (v/v). After incubation overnight
at −20°C, insoluble material was centrifuged at 42,000×g
for 10 min at 4°C. Pellets were washed three times with
pure acetone containing 2-mercaptoethanol, air dried,
and solubilized in 9 M urea, 4% 3-((3-cholamidopropyl)
dimethylammonio)-1-propanesulfonic acid (w/v), 0.05%
Triton X100 (v/v), and 65 mM dithiothreitol (DTT). Protein
content was estimated using the Bradford method [50].
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One-Dimension Electrophoresis
Saliva samples (50 μg) were separated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
using 11% acrylamide gels (1.5 mm thick) according to
Laemmli [51]. Gels were stained with the silver staining
procedure of Vorum [52].
Two-Dimensional Gel Electrophoresis
Precast 18 cm IPG strips pH 4–7 (Amersham Biosciences,
Orsay, France) were rehydrated directly overnight with
protein samples (100 μg). Isoelectric focusing was carried
out using the IPGphor™ isoelectric focusing system for a
total of ca 70,000 V.h. Thereafter, strips were equilibrated
for 15 min in 6 M urea, 50 mM Tris HCl buffer at pH 8.8,
30% glycerol (v/v), 2% SDS (w/v), and 65 mM DTT, and
then for 15 min in the same solution with 65 mM
iodoacetamide instead of DTT. Proteins were finally
separated on 12% SDS-polyacrylamide gels, at constant
voltage (150 V) and 10°C, using an Iso-DALT electropho-
resis unit (Amersham Biosciences). Gels were stained with
colloidal Coomassie blue [53]. Gel images were digitalized
at 300 dpi with a GS 710 densitometer (Biorad, Hercules,
CA, USA) and analyzed using the Progenesis software
(Non-linear Dynamics, Newcastle upon Tyne, UK).
Table 1 A review of previous processing protocols used for proteomic analysis of saliva









54 Stimulated parotid saliva Ice No No −20°C HPLC and N-terminal
sequencing
20 Whole saliva Unknown No No −20°C SDS-PAGE and MALDI-TOF
21 Stimulated glandular
and whole saliva
Ice No Centrifugation −20°C 2DE and MALDI-TOF





Unknown No Centrifugation Unknown 2DE and MALDI-TOF-TOF
26 Unstimulated whole
saliva
Ice Yes Centrifugation −20°C 2DE and MALDI-TOF, Q-TOF,
N-terminal sequencing and
Western blotting
25 Whole saliva Unknown No Centrifugation No storage:
direct analysis




Unknown No Centrifugation Unknown 2D LC-MS
27 Stimulated parotid saliva Ice No Centrifugation −20°C 2DE and MALDI-TOF MALDI-
TOF-TOF and Q-TOF
29 Whole saliva Ice Yes Centrifugation −80°C Shotgun proteomics and 2DE
and MALDI-TOF
30 Stimulated whole saliva Ice Yes Centrifugation −80°C 2DE and MALDI-TOF
33 Unstimulated whole
saliva
Unknown No Centrifugation Unknown FFE and LC-MS/MS
31 Stimulated whole saliva Ice Yes Centrifugation −80°C 2DE and MALDI-TOF
32 Stimulated whole saliva Ice Yes Centrifugation −80°C 2DE and MALDI-TOF
34 Stimulated whole and
parotid saliva




Unknown No Centrifugation −80°C 2DE and MALDI-TOF
36 Parotid saliva Ice No Centrifugation −80°C 2D-DIGE and SELDI-TOF
37 Unstimulated whole
saliva, parotid
Ice No Filtration −80°C 2DE and MALDI-TOF
38 Unstimulated whole
saliva






Unknown Yes Centrifugation Ice, −20°C and
−80°C
SELDI-TOF
MS = mass spectrometry, SELDI = surface enhanced laser desorption/ionization
Clin Proteom (2007) 3:13–21 15
Image Analysis
Gel images were analyzed in triplicate with the Progenesis
Workstation software v.2003.2 (Perkin Elmer Life Sciences,
Cambridge, UK). An automatic averaged gel experiment
was performed with single analytic gels using the control
sample gels as reference. For each sampling time, eight
areas were selected and compared. Images were first
warped to the reference gel and areas were then matched.
A combined algorithm warping and matching was used.
The “progenesis background” was used as the background
method and the spot volume was determined as percentage
of total volume of all spots on respective gels.
Matrix-Assisted Laser Desorption/Ionization-TOF Mass
Spectrometry Analysis
Spots were excised from gels after two-dimensional electro-
phoresis by hand and processed using a Packard Multiprobe
II liquid handling robot (Perkin Elmer, Courtaboeuf,
France). After washing with water, 25 mM ammonium
bicarbonate, acetonitrile/25 mM ammonium bicarbonate
(1:1, v/v) and acetonitrile, gel fragments were dried at 37°C.
Protein digestion was carried out at 37°C for 5 h after addition
of 0.125 μg trypsin. Resulting fragments were extracted twice
with 50 μL of acetonitrile/water (1:1, v/v) containing 0.1%
trifluoroacetic acid for 15 min. Pooled supernatants were
concentrated to a final volume of ca 20 μL. Peptides were
desalted and concentrated to a final volume of 3 μL with
C18 Zip-Tip microcolumns and immediately spotted onto
the matrix-assisted laser desorption/ionization (MALDI)
target by the robot. Mass spectra were recorded in the
reflector mode on a BiFlex III MALDI-TOF mass spec-
trometer (Bruker Daltonics, Bremen, Germany). Automatic
annotation of monoisotopic masses was performed using
Bruker’s SNAPTM procedure. The MASCOT search engine
software (Matrix Science, London, UK) was used to search
the NCBInr database. The following parameters were used:
mass tolerance of 100 ppm, a minimum of five peptides
matching to the protein, carbamidomethylation of cysteine
as fixed modification, oxidation of methionine, and pyro-
glutamylation of glutamine as variable modifications and
one missed cleavage allowed.
Results
Collection and Storage of Saliva Samples
Stimulated saliva was collected between 9 a.m. and 10 a.m.
A male volunteer (age, 33 years) was asked to refrain from
eating, drinking, smoking, or oral hygiene procedures, and
a water mouth-rinse was required prior to sample collec-
tion. Stimulated saliva was collected on ice and clarified by
centrifugation to eliminate mucine, cell debris, and insolu-
ble material. A control sample was kept without centrifu-
gation (unclear saliva). Samples (1 ml) of clear saliva were
aliquoted into 1.5-ml microtubes and incubated at either
−80, −20, 4, and 20°C. A control sample (0 min) was
frozen at −20°C immediately after collection. The kinetics
of storage was studied with samples kept at both 4 and
20°C for 10 min, 1 h, 1 day, 7 days, and 30 days. A cocktail
of protease inhibitor was added to a sample maintained at
both 4 and 20°C for 30 days.
One-Dimensional Electrophoresis Analysis of Stored Saliva
The same volume of clear or unclear saliva samples was
separated by SDS-PAGE (Fig. 1). According to such one-
dimensional electrophoresis, only profile changes of pro-
teins of similar molecular weights could be observed.
A large diversity of molecular weights was observed
with the initial sample frozen immediately after collection
(Fig. 1a, lane 1). Major bands were observed close to 50
and 15 kDa, corresponding to native alpha-amylase and
cystatins, respectively. Minor and diffuse bands were
observed between 50 and 20 kDa, corresponding to an
abundant variety of salivary proteins. According to the
storage kinetics, no major changes were observed on
protein profiles of samples stored for 60 min at ambient
temperature (Fig. 1a, lane 3). At 1 day, the band intensity
just below the native alpha-amylase seemed to be less
intense. At 7 days, the intensity of the native alpha-amylase
band (57 kDa) decreased slightly, resulting in several bands
between 35 and 25 kDa. This phenomenon seemed to be
enhanced after 30 days storage at ambient temperature
(Fig. 1a, lane 6). The addition of protease inhibitors was
not able to block such degradation; no real difference was
observed at 30 days between samples containing cocktail
inhibitors or not.
In contrast, when saliva was stored at 4°C, no such
degradation was observed until 7 days (Fig. 1b, lane 4).
From days 7 to 30, the protein profile seemed to be slightly
less intense in the molecular weight range between 50 and
25 kDa, but without any band appearance. The addition
of protease inhibitors successfully blocked such degrada-
tion at day 30 (Fig. 1b, lane 6). In contrast, when in-
soluble material was not removed, saliva proteins were
completely disappeared at either 4 or 20°C (Fig. 1a, lane 8,
and Fig. 1b, lane 7, respectively). In this case, proteins were
certainly degraded by proteases from bacteria and cells of
the oral cavity. The storage of saliva samples for 30 days
at −20 and −80°C allowed a complete preservation of saliva
proteins, lanes 8 and 9, respectively (Fig. 1b).
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Two-Dimensional Electrophoresis Analysis of Stored
Saliva
To obtain more detailed information, two-dimensional elec-
trophoresis was used to analyze changes in specific protein
groups. Based on the results of one-dimensional analysis, the
times at which protein degradation was most affected were
selected for the two-dimensional electrophoresis separation:
in addition to control samples (0 day and 30 days with
protease inhibitors), we selected samples stored at 20°C for
1, 7, and 30 days to be analyzed. The 30 major protein spots
were selected on two-dimensional gels (Fig. 2) and
identified by peptide mass fingerprinting (Table 2). To com-
pare protein amount during storage times, we decided to
group proteins from the same family and/or gel area (Fig. 2
and Table 2). All the areas were calculated as a mean of
three replicates of the same extract and were matched
together to analyze the evolution of relative intensity
according to the storage time (Fig. 3). Areas A to D were
strongly affected by storage time at 20°C. Area A,
corresponding to serum albumin, disappeared on the
bidimensional map from 1 day and only half of the spot
intensity was maintained at 30 days when a protease
inhibitor cocktail was added to the sample. In the case of
area B, the quantity of salivary acidic prolin rich protein
(PRP) decreased dramatically up to 7 days at ambient
temperature, with only a small amount of the corresponding
spots still observable at days 7 and 30. The same result was
obtained with spots of area C, corresponding to prolactin
inducible proteins and salivary acidic protein-1. Spot
identified as salivary cystatins SA-1 (area D) had disap-
peared totally by day 7, showing its low stability at 20°C.
The addition of a protease inhibitor cocktail did not affect
the degradation of these proteins after 30 days storage at
ambient temperature. The protease inhibitor cocktail tablets
used (Complete Mini®, Roche) were designed to inhibit
mainly serine-, cysteine- and metallo-proteases. Neverthe-
less, the relatively quick degradation of proteins could be
attributed to residual protease activity or to the presence of
acidic proteases such as aspartic protease.
Fig. 2 Two-dimensional electrophoresis of 100 μg of salivary
proteins extracted from the control sample (0 min). Proteins were
resolved using pH 4–7 IPG and 12% SDS-PAGE, and the gel was
stained using Coomassie blue. The 30 most abundant proteins were
reported and identified by peptide mass fingerprint MALDI-TOF (i.e.,
see Table 2)
Fig. 1 One-dimensional SDS-PAGE separation of salivary proteins.
a lanes 1 to 6: clear saliva stored at 20°C for 0 min (control sample),
10 min, 60 min, 1 day, 7 days, and 30 days; lane 7: clear saliva stored
at 20°C for 30 days with a protease inhibitor cocktail; lane 8: unclear
saliva (without centrifugation) stored at 20°C for 30 days. b lanes 1 to
5: clear saliva stored at 4°C for 10 min, 60 min, 1 day, 7 days and 30
days; lane 6: clear saliva stored at 4°C for 30 days with a protease
inhibitor cocktail; lane 7: unclear saliva (without centrifugation)
stored at 4°C for 30 days; lane 8: clear saliva stored at −20°C for 30
days; lane 9: clear saliva stored at −80°C for 30 days
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Table 2 Identification of the 30 most abundant spots from the two-dimensional gel of whole saliva (see Fig. 2), by peptide mass fingerprint
MALDI-TOF
No Group Protein name Ref. % Cov. MW (kDa) theoretical Observed pI theoretical Observed
1 A Serum albumin P02768 29 66.5 68 5.67 5.5
2 A Serum albumin P02768 25 66.5 68 5.67 5.6
3 A Serum albumin P02768 25 66.5 68 5.67 5.8
4 A Serum albumin P02768 27 66.5 68 5.67 6
5 A Serum albumin P02768 25 66.5 68 5.67 6.2
6 F Salivary-amylase P04745 42 55.9 59 6.34 5.5
7 F Salivary-amylase P04745 33 55.9 59 6.34 5.8
8 F Salivary-amylase P04745 28 55.9 59 6.34 6
9 F Salivary-amylase P04745 51 55.9 59 6.34 6.1
10 F Salivary-amylase P04745 50 55.9 59 6.34 6.3
11 F Salivary-amylase P04745 51 55.9 59 6.34 6.5
12 F Salivary-amylase P04745 50 55.9 59 6.34 6.7
13 G Zinc-alpha-2-glycoprotein P25311 52 32.1 42 5.58 5.1
14 G Zinc-alpha-2-glycoprotein P25311 53 32.1 42 5.58 5.3
15 G Zinc-alpha-2-glycoprotein P25311 57 32.1 42 5.58 5.5
16 G Zinc-alpha-2-glycoprotein P25311 53 32.1 42 5.58 5.7
17 B Salivary acidic PRP P02810 36 15.4 26 4.63 4.1
18 B Salivary acidic PRP P02810 42 15.4 25 4.63 4.2
19 C Prolactin inducible P12273 38 13.5 18 5.47 4.2
20 C Prolactin inducible P12273 50 13.5 18 5.47 4.5
21 C Prolactin inducible P12273 43 13.5 18 5.47 5
22 C Salivary acidic protein 1 P01036 27 14.2 16 4.83 4.2
23 C Salivary acidic protein 1 P01036 29 14.2 16 4.83 4.4
24 C Salivary acidic protein 1 P01036 34 14.2 16 4.83 4.7
25 D Salivary cystatin SA-1 P01037 40 14.3 16 6.92 7
26 E Salivary-amylase P04745 34 55.9 30 6.34 6.4
27 E Salivary-amylase P04745 22 55.9 35 6.34 6.5
28 E Salivary-amylase P04745 35 55.9 30 6.34 6.7
29 E Salivary-amylase P04745 43 55.9 28 6.34 6.8
30 E Salivary-amylase P04745 27 55.9 27 6.34 7.1
Protein reference (Ref.) corresponds to the Swiss-Prot/NCBI accession number; sequence coverage (% cov.) is given as percentage
Fig. 3 Total protein amount of
spot groups from the two-
dimensional separation (i.e., see
Fig. 2) as a function of storage
time at ambient temperature.
a–g groups a–g
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In contrast, the opposite result was obtained with areas
E, F, and G, in which no real degradation was observed.
The corresponding proteins, alpha-amylase (groups E and
F) and zinc-alpha-2 glycoprotein (group G), seemed to
resist degradation up to 30 days storage at ambient
temperature. Nevertheless, after 1 day of storage, a 15%
decrease of area F spot intensities was observed with a
concomitant increase of area E spots. It could be hy-
pothesized that native alpha-amylase was degraded to
constitute a part of alternative alpha-amylase forms. These
lower-molecular-weight forms of alpha-amylase were
previously described as a complex but stable protein pat-
tern [31]. Certainly a part of these alternative alpha-
amylase spots remained from the degradation of the native
alpha-amylase form [3, 4], but another part, which con-
stitutes the stable pattern [31], seemed not to be affected
by degradation. The example of these alternative alpha-
amylase spots clearly demonstrated the importance of a
strong control of protease actions to understand and com-
pare proteomes.
Concluding Remarks
As saliva is now frequently used as a diagnostic biological
fluid, our work demonstrated the necessity for a well-
controlled storage protocol of saliva samples to ensure
quantitative and reproducible clinical analysis. Of course,
storage temperatures such as −20 and −80°C are now
commonly used to store biospecimens, but such storage
conditions could be considered as excessive owing to the
fact that saliva contains a high amount of protease
inhibitors which can prevent protein degradation.
Our results clearly showed the weak stability of several
salivary proteins. According to one- and two-dimensional
electrophoresis studies (Table 3), the stability of clear
saliva was preserved until 1 day at 20°C and 7 days at 4°C.
After 30 days at 20°C, almost half of the major salivary
proteins were degraded even if a protease inhibitor cocktail
was added to the sample.
According to these results, and in agreement with
Schipper et al. [39], the protocol used by Hu et al. [29]
seemed to be the best to maintain the optimum stability of
saliva proteins. In case of a clinical comparison with a
pathological condition, control saliva samples should be
collected from a healthy nonsmoking subject, in the
morning, at least 2 h after eating, and the mouth should
be rinsed with water. After collection, saliva samples
should be stored in a freezer at −20°C, and during
sampling, saliva should be kept on ice with a protease
inhibitor cocktail and centrifuged to remove insoluble
material and then stored at −80°C.
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20°C 0 − + − None
20°C 10 min − + − /
20°C 60 min − + − /
20°C 1 day − + +/− A
20°C 7 days − + + A, B, C, D, G
20°C 30 days − + + A, B, C, D, G
20°C 30 days + + + A, B, C, D, G
20°C 30 days − − +++ /
4°C 10 min − + − /
4°C 60 min − + − /
4°C 1 day − + − /
4°C 7 days − + +/− /
4°C 30 days − + +/− /
4°C 30 days + + − /
4°C 30 days − − +++ /
−20°C 30 days − + − /
−80°C 30 days − + − /
a One-dimensional electrophoresis experiment
b Two-dimensional electrophoresis experiment
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